144 related articles for article (PubMed ID: 31664085)
1. Detecting TP53 mutations in diagnostic and archival liquid-based Pap samples from ovarian cancer patients using an ultra-sensitive ddPCR method.
Arildsen NS; Martin de la Fuente L; Måsbäck A; Malander S; Forslund O; Kannisto P; Hedenfalk I
Sci Rep; 2019 Oct; 9(1):15506. PubMed ID: 31664085
[TBL] [Abstract][Full Text] [Related]
2. Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma.
Krimmel-Morrison JD; Ghezelayagh TS; Lian S; Zhang Y; Fredrickson J; Nachmanson D; Baker KT; Radke MR; Hun E; Norquist BM; Emond MJ; Swisher EM; Risques RA
Gynecol Oncol; 2020 Feb; 156(2):407-414. PubMed ID: 31839337
[TBL] [Abstract][Full Text] [Related]
3. Detection of TP53 Clonal Variants in Papanicolaou Test Samples Collected up to 6 Years Prior to High-Grade Serous Epithelial Ovarian Cancer Diagnosis.
Paracchini L; Pesenti C; Delle Marchette M; Beltrame L; Bianchi T; Grassi T; Buda A; Landoni F; Ceppi L; Bosetti C; Paderno M; Adorni M; Vicini D; Perego P; Leone BE; D'Incalci M; Marchini S; Fruscio R
JAMA Netw Open; 2020 Jul; 3(7):e207566. PubMed ID: 32609349
[TBL] [Abstract][Full Text] [Related]
4. Genomic instability analysis in DNA from Papanicolaou test provides proof-of-principle early diagnosis of high-grade serous ovarian cancer.
Paracchini L; Mannarino L; Romualdi C; Zadro R; Beltrame L; Fuso Nerini I; Zola P; Laudani ME; Pagano E; Giordano L; Fruscio R; Landoni F; Franceschi S; Dalessandro ML; Canzonieri V; Bocciolone L; Lorusso D; Bosetti C; Raspagliesi F; Garassino IMG; ; D'Incalci M; Marchini S
Sci Transl Med; 2023 Dec; 15(725):eadi2556. PubMed ID: 38055801
[TBL] [Abstract][Full Text] [Related]
5. Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues.
Krimmel JD; Schmitt MW; Harrell MI; Agnew KJ; Kennedy SR; Emond MJ; Loeb LA; Swisher EM; Risques RA
Proc Natl Acad Sci U S A; 2016 May; 113(21):6005-10. PubMed ID: 27152024
[TBL] [Abstract][Full Text] [Related]
6. Identification of Novel Somatic
Garziera M; Cecchin E; Canzonieri V; Sorio R; Giorda G; Scalone S; De Mattia E; Roncato R; Gagno S; Poletto E; Romanato L; Sartor F; Polesel J; Toffoli G
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783665
[TBL] [Abstract][Full Text] [Related]
7. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance.
Salani R; Kurman RJ; Giuntoli R; Gardner G; Bristow R; Wang TL; Shih IM
Int J Gynecol Cancer; 2008; 18(3):487-91. PubMed ID: 17692090
[TBL] [Abstract][Full Text] [Related]
8. TP53 mutation in ovarian carcinoma.
Murphy M; McManus DT; Toner PG; Russell SE
Eur J Cancer; 1997 Jul; 33(8):1281-3. PubMed ID: 9301456
[TBL] [Abstract][Full Text] [Related]
9. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
10. Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing.
Cole AJ; Dwight T; Gill AJ; Dickson KA; Zhu Y; Clarkson A; Gard GB; Maidens J; Valmadre S; Clifton-Bligh R; Marsh DJ
Sci Rep; 2016 May; 6():26191. PubMed ID: 27189670
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.
Kinde I; Bettegowda C; Wang Y; Wu J; Agrawal N; Shih IeM; Kurman R; Dao F; Levine DA; Giuntoli R; Roden R; Eshleman JR; Carvalho JP; Marie SK; Papadopoulos N; Kinzler KW; Vogelstein B; Diaz LA
Sci Transl Med; 2013 Jan; 5(167):167ra4. PubMed ID: 23303603
[TBL] [Abstract][Full Text] [Related]
12. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
[TBL] [Abstract][Full Text] [Related]
13. Droplet digital polymerase chain reaction assay and peptide nucleic acid-locked nucleic acid clamp method for RHOA mutation detection in angioimmunoblastic T-cell lymphoma.
Tanzima Nuhat S; Sakata-Yanagimoto M; Komori D; Hattori K; Suehara Y; Fukumoto K; Fujisawa M; Kusakabe M; Matsue K; Wakamatsu H; Shimadzu M; Chiba S
Cancer Sci; 2018 May; 109(5):1682-1689. PubMed ID: 29493850
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers.
Wang Y; Li L; Douville C; Cohen JD; Yen TT; Kinde I; Sundfelt K; Kjær SK; Hruban RH; Shih IM; Wang TL; Kurman RJ; Springer S; Ptak J; Popoli M; Schaefer J; Silliman N; Dobbyn L; Tanner EJ; Angarita A; Lycke M; Jochumsen K; Afsari B; Danilova L; Levine DA; Jardon K; Zeng X; Arseneau J; Fu L; Diaz LA; Karchin R; Tomasetti C; Kinzler KW; Vogelstein B; Fader AN; Gilbert L; Papadopoulos N
Sci Transl Med; 2018 Mar; 10(433):. PubMed ID: 29563323
[TBL] [Abstract][Full Text] [Related]
15. Ultra-Sensitive TP53 Sequencing for Cancer Detection Reveals Progressive Clonal Selection in Normal Tissue over a Century of Human Lifespan.
Salk JJ; Loubet-Senear K; Maritschnegg E; Valentine CC; Williams LN; Higgins JE; Horvat R; Vanderstichele A; Nachmanson D; Baker KT; Emond MJ; Loter E; Tretiakova M; Soussi T; Loeb LA; Zeillinger R; Speiser P; Risques RA
Cell Rep; 2019 Jul; 28(1):132-144.e3. PubMed ID: 31269435
[TBL] [Abstract][Full Text] [Related]
16. Clonal Evolution of
Garziera M; Cecchin E; Giorda G; Sorio R; Scalone S; De Mattia E; Roncato R; Gagno S; Poletto E; Romanato L; Ecca F; Canzonieri V; Toffoli G
Cells; 2019 Oct; 8(10):. PubMed ID: 31581548
[TBL] [Abstract][Full Text] [Related]
17. Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma.
Kim YM; Lee SW; Lee YJ; Lee HY; Lee JE; Choi EK
J Gynecol Oncol; 2019 May; 30(3):e32. PubMed ID: 30887755
[TBL] [Abstract][Full Text] [Related]
18. Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors.
Tworek H; Peng R; Fetzer S; Werness BA; Piver MS; Allen HJ; DiCioccio RA
Cancer Genet Cytogenet; 1999 Jul; 112(2):105-18. PubMed ID: 10686936
[TBL] [Abstract][Full Text] [Related]
19. TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Zhang GN; Liu H; Huang JM; Wang L; Zhao JS; Li C; Mi K; Zhu Y; Cheng J; Zha X
Gynecol Oncol; 2014 Mar; 132(3):752-7. PubMed ID: 24463159
[TBL] [Abstract][Full Text] [Related]
20. Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma.
Choi MC; Hwang S; Kim S; Jung SG; Park H; Joo WD; Song SH; Lee C; Kim TH; Kang H; An HJ
Cancer Res Treat; 2020 Apr; 52(2):634-644. PubMed ID: 32019284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
